Heart Failure
心血管疾病已经成为当今社会致死和致残的首要疾病，各种严重心血管疾病的最终转归是心力衰竭，随着医疗水平的进步，心血管疾病急性期病死率大大降低，但心力衰竭的发病率仍在急剧增加。美国心力衰竭的患者大约有
500 万人，每年新增病例数为 40 万人。我国人群中也呈现上升趋势。目前心力衰竭的治疗包括药物治疗、介入治疗、手术治疗、以及基因和细胞治疗等。以上多种治疗手段在一定程度上提高了心力衰竭治疗的临床疗效，改善了患者的临床症状、提高了生存率、降低了再住院率，
但心力衰竭的防治仍无根本的改善，亦缺乏有效的防治手段，成为心血管疾病研究的关键和核心。最近JCI发表了一系列的总结论文，介绍了近代进展。为此CMBI特搜集了关于Heart
Failure的特别报道，供实践参考。更多文献,请用相关关键词通过CMBI文献查询获取。
- Ventricular remodeling in heart
failure
- Vasopressin antagonism-a future
treatment option in heart failure
- Tolerability of carvedilol in heart
failure
- Thyrotoxicosis-an uncommon cause
of heart failure
- The year in heart failure
- The Use of Vasodilators in the Treatment
of Acute Decompensated Heart Failure
- The use of angiotensin receptor
blockers in the treatment of chronic heart failure
- The update on the rationale, use
and selection of [beta]-blockers in heart failure
- The scientific foundations of cardiac
repair
- The Role of Echocardiography in
the Diagnosis and Management of Heart Failure
- The role of aldosterone and aldosterone-receptor
antagonists in heart failure
- The evolving challenge of chronic
heart failure management
- The Effects of Beta Blockers on
Morbidity and Mortality in Heart Failure
- The crucial role of patient education
in heart failure
- Strategies to improve the use of
evidence-based heart failure therapies
- Strategies for Developing Biomarkers
of Heart Failure
- Special considerations for carvedilol
use in heart failure
- Risk Stratification for In-Hospital
Mortality in Acutely Decompensated Heart Failure
- Myocardial Neovascularization by
Adult Bone Marrow-Derived Angioblasts
- Myoblast-Based Cell Transplantation
- Human Embryonic Stem Cells for Myocardial
Regeneration
- Heart Dysfunction-Is Cell Transplantation
a Potential Therapy
- Bone-Marrow Stem Cells as a Source
for Cell Therapy
- Autologous Stem Cells for Functional
Myocardial Repair
- Prognostic implications of echocardiography
in advanced heart failure
- pharmacotherapy for chronic heart
failure
- Pharmacotherapy for Chronic Heart
Failure
- Pharmacogenomics of heart failure
- Pathway for the Management of Acute
Heart Failure
- Optimizing treatment of chronic
decompensated heart failure in the outpatient setting
- Nonselective versus selective beta-blockers
in the management of chronic heart failure
- Non-compliance in patients with
heart failure
- Measurement of end points in heart
failure trials
- Management of diastolic heart failure
- Management of chronic heart failure
- Learning congestive heart failure
in the postgenomic age
- Importance of in-hospital initiation
of evidence-based medical therapies for heart failure-a review
- Heart failure therapy in special
populations
- Diuretic usage in heart failure
- Digitalis therapy for patients in
clinical heart failure
- Diastolic Heart Failure
- Diagnosis and assessment of the
heart failure patient
- Design of therapy for advanced heart
failure
- Death begets failure in the heart
- Cytokines in Depression and Heart
Failure
- Current guidelines in the management
of chronic heart failure
- Cost-Effectiveness of Cardiac Resynchronization
Therapy in Patients with Symptomatic Heart Failure
- Coronary Artery Surgery for Ischaemic
Heart Failure
- congestive heart failure in the
postgenomic age
- Cardiac Resynchronization in Patients
with Symptomatic Heart Failure
- Cardiac Hormones as Diagnostic Tools
in Heart Failure
- B-Type Natriuretic Peptide and the
Right Heart
- B-type natriuretic Peptide and the
diagnosis of acute heart failure
- B-type Natriuretic Peptide-A Review
of Its Diagnostic, Prognostic, and Therapeutic Monitoring Value in Heart Failure
- Brain Natriuretic Peptide
in the Management of Heart Failure
- The Effects of Beta Blockers on
Morbidity and Mortality in Heart Failure
- Pharmacokinetics and Pharmacodynamics
of Beta Blockers in Heart Failure
- Biologic Rationale for the Use of
Beta-Blockers in the Treatment of Heart Failure
- Beta-Blockers in Heart Failure
- Beta-Blockers in Heart Failure
- Beta Blockers as Anti-Arrhythmic
Agents
- Beta Blocker Therapy After Acute
Myocardial Infarction in Patients with Heart Failure
- Beneficial effects of early initiation
of vasoactive agents in patients
- Association of β-adrenergic receptor
polymorphisms and progression to heart failure
- Anti-beta(1)-adrenergic receptor
antibodies and heart failure
- Anti-adrenergic receptor antibodies
and heart failure
- Angiotensin-Receptor Blockers in
Chronic Heart Failure
- Ambulatory blood pressure monitoring
in heart failure
- Aldosterone antagonism and congestive
heart failure
- A Systematic Review of the Diagnostic
Accuracy of Natriuretic Peptides for Heart Failure
- A hard look at angiotensin receptor
blockers in heart failure
- Heart failure and the brain
基础相关 - What Is the Role of β-Adrenergic
Signaling in Heart Failure
- Toward transcriptional therapies
for the failing heart
- The Dynamic Interaction Between
Matrix Metalloproteinase Activity and Adverse Myocardial Remodeling
- Regulation of Matrix Metalloproteinases
by Cytokines and Reactive Oxygen-Nitrogen Species in the Myocardium
- MMP Induction and Inhibition in
Myocardial Infarction
- Matrix Metalloproteinases-Pathways
of Induction by Bioactive Molecules
- Possible Interactions Between Inflammatory
Mediators and MMP-TIMP System
- The Matrix Metalloproteinases
- The Adrenergic Pathway and Heart
Failure
- Role of Nitric Oxide in the Pathophysiology
of Heart Failure
- Role of Nitric Oxide in Matrix Remodeling
in Diabetes and Heart Failure
- Role of Mitochondria in Transition
Between Hypertrophy and Heart Failure
- Regulation of mitochondrial proliferation
in the heart
- Reprogramming Cells for Transplantation
- Principles of Low Temperature Cell
Preservation
- Cell Cycle Regulation to Repair
the Infarcted Myocardium
- Cardiomyocyte Transplantation into
the Failing Heart
- Cardiac Tissue Engineering, Ex-Vivo
- Regeneration Hope to Grow a New
Heart Muscle
- Protein kinase cascades in the regulation
of cardiac hypertrophy
- Polymorphisms of β-adrenergic receptors
in heart failure
- NO-redox disequilibrium in the failing
heart and cardiovascular system
- Natriuretic peptides and the management
of heart failure
- MOLECULAR GENETICS AND GENOMICS
OF HEART FAILURE
- Mitochondrial energy metabolism
in heart failure
- Heart failure increases protein
expression and enzymatic activity of heme oxygenase-1 in the lung
- Hard-hearted CRP
- Genetic polymorphisms and heart
failure
- Genetic causes of human heart failure
- Energy metabolism in heart failure
- Effects of Brief Ischemia and Reperfusion
on the Myocardium and the Role of Nitric Oxide
- Cardiac remodeling and failure
- Cardiac remodeling and failure
- calmodulin-dependent protein kinase
II in cardiac hypertrophy and heart failure
- Calcium cycling proteins in heart
failure
- Biologic Rationale for the Use of
Beta-Blockers in the Treatment of Heart Failure
- Biochemical markers of myocyte injury
in heart failure
- B-ANP-The Therapeutic Effect of
Natriuretic Peptides in Heart Failure
- Autoimmune heart failure
- Assessment of endothelial damage
and dysfunction-heart failure
- Alveolar-Capillary Membrane Dysfunction
in Heart Failure
- Altered intracellular Ca2+ handling
in heart failure
- A systematic review of large scale
and heterogeneous gene array data in heart failure
- A systematic review of large scale
and heterogeneous gene array data in heart failure-
- Oxygen, oxidative stress, hypoxia,
and heart failure
- Heart failure–a challenge to our
current concepts of excitation-contraction coupling
临床相关
Last Modified: 2005-05-01